Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
BACKGROUND: ESR1 mutation in circulating cell-free DNA (cfDNA) is emerging as a noninvasive biomarker of acquired resistance to endocrine therapy, but there is a paucity of data comparing the status of ESR1 gene in cfDNA with that in its corresponding tumor tissue. The objective of this study is to...
Main Authors: | Takashi Takeshita, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Mai Tomiguchi, Aiko Sueta, Keiichi Murakami, Yoko Omoto, Hirotaka Iwase |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-10-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523317301523 |
Similar Items
-
Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
by: Takashi Takeshita, et al.
Published: (2017-11-01) -
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
by: Takashi Takeshita, et al.
Published: (2018-02-01) -
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
by: Aiko Sueta, et al.
Published: (2014-01-01) -
PTIP associated protein 1, PA1, is an independent prognostic factor for lymphnode negative breast cancer.
by: Takashi Takeshita, et al.
Published: (2013-01-01) -
The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer.
by: Takuya Shiota, et al.
Published: (2016-01-01)